- Home
- CPBI vs FLNA Comparison
CPBI vs FLNA Comparison
Compare CPBI & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | FLNA |
|---|---|---|
| Founded | 2023 | 1998 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.5M | 61.8M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CPBI | FLNA |
|---|---|---|
| Price | $18.38 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.9K | ★ 395.0K |
| Earning Date | 06-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.52 | $1.16 |
| 52 Week High | $18.75 | $2.03 |
Technical Indicators
Market Signals| Indicator | CPBI | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.80 | 55.64 |
| Support Level | $16.88 | $1.16 |
| Resistance Level | N/A | $1.80 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 74.29 | 79.16 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.